Trejo-Acuña JR, Navarrete-Franco G, Olivares-Oropeza NA

Language: Spanish
References: 17
Page: 19-24
PDF size: 251.60 Kb.

ABSTRACT

Mastocytosis comprises a heterogeneous group of diseases characterized by abnormal accumulation of mastocytes in one or several organs. There are two types: systemic and cutaneous. Within cutaneous the most frequent variety corresponds to urticaria pigmentosa, that typically occurs in children and is characterized by a maculopapular dermatosis, in brown tones, disseminated, that respect face, palms and soles. The diagnosis is clinical, corroborating the presence of mastocyte infiltrate in the histopathological study. The treatment is directed to the control of the symptoms since a curative treatment is not yet available.

REFERENCES

1. Berezowska S, Flaig MJ, Ruëff F, Walz C, Haferlach T, Krokowski M et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol. 2014; 27: 19-29.

2. Conde FI, Dos Anjos TM, Freitas I, Selores M, Alves R, Lima M. Adult mastocytosis: a review of the Santo António Hospital’s experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease. An Bras Dermatol. 2014; 89: 59-66.

3. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25: 603-625.

4. Barete S. Mastocitosis. EMC-Dermatología. 2013; 47: 1-16.

5. Méni C, Bruneau J, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Damaj G, Hadj-Rabia S et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015; 172: 642-651.

6. Akoglu G, Erkin G, Cakir B, Boztepe G, Sahin S, Karaduman A et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol. 2006; 20: 969-973.

7. Noack F, Escribano L, Sotlar K, Nunez R, Schuetze K, Valent P et al. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cell without evidence of c-kit mutation ASP-816-VAL. Leuk Lymphoma. 2003; 44: 313-319.

8. Fuller SJ. New insights into the pathogenesis, diagnosis, and management of mastocytosis. Hematol Oncol Clin North Am. 2012; 26: 1143-1168.

9. Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol. 2001; 42: 15-21.

10. Cardet JC, Akin C, Lee MJ. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother. 2013; 14: 2033-2045.

11. Middelkamp Hup MA, Heide R, Tank B, Mulder PG, Oranje AP. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002; 16: 115-120.

12. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001; 25: 519-528.

13. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res. 2001; 25: 553-562.

14. Alvarez-Twose I, Vañó-Galván S, Sánchez-Muñoz L, Morgado JM, Matito A, Torrelo A et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012; 67: 813-821.

15. Kristensen T, Vestergaard H, Bindslev-Jensen C, Møller MB, Broesby-Olsen S; Mastocytosis Centre, Odense University Hospital (MastOUH). Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol. 2014; 89: 493-498.

16. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108: 2366-2372.

17. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011; 12: 259-270.